Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
Open accessAbstract
AIM: This study aimed to compare 6-month adherence to therapy with exenatide once weekly (Bydureon(®)) vs liraglutide once daily (Victoza(®)) in patients with type 2 diabetes under primary care in Germany. METHODS: A nationwide longitudinal prescription database (LRx), (between January 2011 and September 2014) was used to analyze adherence to therapy. The proportion of days covered (PDC) by prescription was used as a measure of adherence in the 6-month postindex period. Logistic regression analyses were performed to investigate the associations between glucagon-like peptide-1 receptor agonist therapy adjusting for age, sex, and cotherapy. RESULTS: Therapy was initiated in 5,449 patients with exenatide once weekly (age: 59.7±11.8 years; 51.4% were male) and in 24,648 patients with liraglutide once daily (age: 59.4±11.4 years; 49.7% were male). The median PDC was 0.88 for exenatide once weekly and 0.77 for liraglutide once daily (P<0.05). Once-weekly exenatide was associated with significantly higher adherence. Odds ratio (95% confidence interval) for having a PDC of ≥0.80 was 1.78 (1.62-1.96) for exenatide once weekly compared with liraglutide once daily after adjusting for age, sex, and cotherapy. CONCLUSION: Adherence to treatment with exenatide once weekly was significantly increased compared to that with liraglutide once daily over 6 months in patients with type 2 diabetes.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The finding that patients on weekly dosing regimens are more adherent than those on daily dosing regimens is consistent with other studies.
“The finding that patients on weekly dosing regimens are more adherent than those on daily dosing regimens is also consistent with other studies using administrative and electronic medical records datasets across Europe and the USA.”
From Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK (2022) · cites this paper as [24]
The Conclusion reports better adherence with once-weekly than once-daily GLP-1 receptor agonist treatment, and the Discussion describes a consistent US administrative-claims study. The Methods identify this paper’s German data as a prescription-reimbursement database, not electronic medical records, so that dataset description is not supported for this study. (LLM, conf=0.82)
Experimental — accuracy not yet measuredThe results of this study are overall consistent with previous reports on adherence to GLP-1 RAs.
“Thus, the results of this study are overall consistent with previous reports.”
From Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK (2022) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Adherence to Therapies in Patients with Type 2 Diabetes
García‐Pérez, L., Álvarez, M., Dilla, T., Gil-Guillén, V. F., & Orozco‐Beltrán, D. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0034-y · Cited by 738 · see citing works
Gute Praxis Sekundärdatenanalyse (GPS): Leitlinien und Empfehlungen
Swart, E., Gothe, H., Geyer, S., Jaunzeme, J., Maier, B., Grobe, T., & Ihle, P. (2015) · Das Gesundheitswesen · doi:10.1055/s-0034-1396815 · Cited by 445 · see citing works
Long-Acting Glucagon-Like Peptide 1 Receptor Agonists
Garber, A. J. (2011) · Diabetes Care · doi:10.2337/dc11-s231 · Cited by 350 · see citing works
The Impact of Treatment Noncompliance on Mortality in People With Type 2 Diabetes
Currie, C. J., Peyrot, M. F., Morgan, C. L., Poole, C., Jenkins‐Jones, S., Rubin, R. R., Burton, C. M., & Evans, M. (2012) · Diabetes Care · doi:10.2337/dc11-1277 · Cited by 252 · see citing works
Iglay, K., Cartier, S. E., Rosen, V. M., Zarotsky, V., Rajpathak, S. N., Radican, L., & Tunceli, K. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1053048 · Cited by 157 · see citing works
Patient perspectives on once‐weekly medications for diabetes
Polonsky, W. H., Fisher, L., Hessler, D., Bruhn, D. F., & Best, J. H. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01327.x · Cited by 131 · see citing works
Buysman, E. K., Liu, F., Hammer, M., & Langer, J. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0199-z · Cited by 101 · see citing works
Johnston, S. S., Nguyen, H. P., Felber, E., Cappell, K. A., Nelson, J. K., Chu, B. C., & Kalsekar, I. D. (2014) · Advances in Therapy · doi:10.1007/s12325-014-0166-0 · Cited by 71 · see citing works
The impact of treatment non-compliance on mortality in people with type 1 diabetes
Currie, C. J., Peyrot, M. F., Morgan, C. L., Poole, C., Jenkins‐Jones, S., Rubin, R. R., Burton, C. M., & Evans, M. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.10.006 · Cited by 67 · see citing works
Combining GLP ‐1 receptor agonists with insulin: therapeutic rationales and clinical findings
Holst, J. J., & Vilsbøll, T. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01628.x · Cited by 63 · see citing works
Ulrich, W. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.06.003 · Cited by 47 · see citing works
Malmenäs, M., Bouchard, J. R., & Langer, J. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.03.021 · Cited by 43 · see citing works
Use of a German longitudinal prescription database (LRx) in pharmacoepidemiology
Richter, H., Dombrowski, S., Hamer, H. M., Hadji, P., & Kostev, K. (2015) · PubMed Central · doi:10.3205/000218 · Cited by 34 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · see citing works
Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems
Baryakova, T. H., Pogostin, B. H., Langer, R., & McHugh, K. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00670-0 · Cited by 499 · see citing works
Gorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., Castro, A., Cebrián-Cuenca, A., de Torres-Sánchez, A., García-de-Lucas, M. D., Núñez, J., Obaya, J. C., Soler, M. J., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010145 · Cited by 358 · see citing works
Weiss, T., Yang, L., Carr, R. D., Pal, S., Sawhney, B., Boggs, R., Rajpathak, S., & Iglay, K. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002517 · Cited by 152 · see citing works
Efficacy of semaglutide in a subcutaneous and an oral formulation
Meier, J. J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645617 · Cited by 146 · see citing works
Weiss, T., Carr, R. D., Pal, S., Yang, L., Sawhney, B., Boggs, R., Rajpathak, S., & Iglay, K. (2020) · Patient Preference and Adherence · doi:10.2147/ppa.s277676 · Cited by 126 · see citing works
Tan, H. C., Dampil, O. A., & Marquez, M. M. (2022) · Journal of the ASEAN Federation of Endocrine Societies · doi:10.15605/jafes.037.02.14 · Cited by 135 · see citing works
Guerci, B., Chanan, N., Kaur, S., Jasso-Mosqueda, J. G., & Lew, E. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0590-x · Cited by 106 · see citing works
Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features
Lyseng-Williamson, K. A. (2019) · Clinical Drug Investigation · doi:10.1007/s40261-019-00826-0 · Cited by 87 · see citing works
Li, Y., Yang, Y., Chen, H., Mei, L., & Zeng, X. (2021) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2021.07.002 · Cited by 85 · see citing works
Rosenstock, J., Juneja, R., Beals, J. M., Moyers, J. S., Ilag, L. L., & McCrimmon, R. J. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnad037 · Cited by 83 · see citing works
Weiss, C. R., Abiola, G. O., Fischman, A. M., Cheskin, L. J., Vairavamurthy, J. P., Holly, B. P., Akinwande, O., Nwoke, F., Paudel, K., Belmustakov, S., et al. (2019) · Radiology · doi:10.1148/radiol.2019182354 · Cited by 77 · see citing works
Heise, T., Chien, J. Y., Beals, J. M., Benson, C., Klein, O., Moyers, J. S., Haupt, A., & Pratt, E. J. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14956 · Cited by 75 · see citing works
Weeda, E. R., Muraoka, A. K., Brock, M. D., & Cannon, J. M. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14060 · Cited by 73 · see citing works
Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance
Almandoz, J. P., Lingvay, I., Morales, J., & Campos, C. (2020) · Clinical Diabetes · doi:10.2337/cd19-0100 · Cited by 74 · see citing works
Clinical perspectives on the use of subcutaneous and oral formulations of semaglutide
Gallwitz, B., & Giorgino, F. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645507 · Cited by 70 · see citing works
Basal weekly insulins: the way of the future!
Rosenstock, J., & Prato, S. D. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154924 · Cited by 63 · see citing works
Frías, J. P., Chien, J. Y., Zhang, Q., Chigutsa, E., Landschulz, W. H., Syring, K. E., Wullenweber, P. K., Haupt, A., & KAZDA, C. M. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00388-6 · Cited by 61 · see citing works
Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment
Wysham, C., BAJAJ, H. S., Prato, S. D., Franco, D. R., Kiyosue, A., Dahl, D. B., Zhou, C., Carr, M. C., Case, M. G., & GONCALVES, L. F. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403953 · Cited by 61 · see citing works
Preclinical Characterization of LY3209590, a Novel Weekly Basal Insulin Fc-Fusion Protein
Moyers, J. S., Hansen, R. J., Day, J. W., Dickinson, C. D., Zhang, C., Ruan, X., Ding, L., Brown, R. M., Baker, H. E., & Beals, J. M. (2022) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001105 · Cited by 61 · see citing works
Bue‐Valleskey, J. M., KAZDA, C. M., Ma, C., Chien, J. Y., Zhang, Q., Chigutsa, E., Landschulz, W. H., Haupt, A., & Frías, J. P. (2023) · Diabetes Care · doi:10.2337/dc22-2396 · Cited by 57 · see citing works
Busch, R. S., & Kane, M. P. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1342509 · Cited by 57 · see citing works
Abramson, A., Halperin, F., Kim, J., & Traverso, G. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.04.022 · Cited by 54 · see citing works
Jain, A., Ali, A., Martínez, J. J. G., HRAMIAK, I. M., Kavia, K., Madsbad, S., Potier, L., Prohaska, B. D., Strong, J. L., & Vilsbøll, T. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13731 · Cited by 47 · see citing works
Chun, J. H., & Butts, A. (2020) · JAAPA · doi:10.1097/01.jaa.0000669456.13763.bd · Cited by 45 · see citing works
Del Prato, S., Kang, J., Trautmann, M. E., Stewart, J., Sorli, C. H., Derwahl, M., Soto, A., & Yoon, K. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14020 · Cited by 43 · see citing works
What do we do now that the long-acting growth hormone is here?
Miller, B. S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.980979 · Cited by 39 · see citing works
Maniatis, A. K., Carakushansky, M., Galcheva, S., Prakasam, G., Fox, L. A., Dankovcikova, A., Loftus, J., Palladino, A., Resa, M. D. L. A., Taylor, C. T., et al. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac117 · Cited by 39 · see citing works
Adamou, A. T., Barkas, F., Milionis, H. J., & Ntaios, G. (2024) · International Journal of Stroke · doi:10.1177/17474930241253988 · Cited by 38 · see citing works
Qin, L., Chen, S., Flood, E. M., Shaunik, A., Romero, B., de la Cruz, M., Alvarez, C., & Grandy, S. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0230-2 · Cited by 35 · see citing works
Self-citationRosenstock, J., SORLI, C. H., TRAUTMANN, M. E., Morales, C., Wendisch, U., DAILEY, G. E., Hompesch, M., Choi, I. Y., Kang, J., Stewart, J. A., et al. (2019) · Diabetes Care · doi:10.2337/dc18-2648 · Cited by 34 · see citing works
Guerci, B., Charbonnel, B., Gourdy, P., Hadjadj, S., Hanaire, H., Marre, M., & Vergès, B. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.01.006 · Cited by 40 · see citing works
Philis‐Tsimikas, A., Bergenstal, R. M., Bailey, T. S., Jinnouchi, H., Thrasher, J. R., Ilag, L. L., Mitra, J., Syring, K. E., & Threlkeld, R. J. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01044-x · Cited by 32 · see citing works
Qin, L., Chen, S., Flood, E. M., Shaunik, A., Romero, B., de la Cruz, M., Alvarez, C., & Grandy, S. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0237-8 · Cited by 32 · see citing works
Self-citationBlevins, T., Dahl, D. B., Manghi, F. P., Murthy, S., Carrasquillo, R. O., Li, X., Chang, A. M., Carr, M. C., & Katz, M. L. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01069-4 · Cited by 33 · see citing works
Ishii, H., Shin, H., Tosaki, T., Haga, T., Nakajima, Y., Shiraiwa, T., Watanabe, N., Koizumi, M., Nakajima, H., Okada, S., et al. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0414-4 · Cited by 31 · see citing works
Bergenstal, R. M., Philis‐Tsimikas, A., Wysham, C., Carr, M. C., Bue‐Valleskey, J. M., Botros, F. T., Blevins, T., & Rosenstock, J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15604 · Cited by 29 · see citing works
Experience of switching from a daily to a less frequent administration of injection treatments
Loftus, J., Yaworsky, A., Roland, C. L., Turner‐Bowker, D. M., McLafferty, M., Su, S., & Lamoureux, R. E. (2022) · PLoS ONE · doi:10.1371/journal.pone.0278293 · Cited by 24 · see citing works
Kim, Y. C., Hsueh, H. T., Shin, M. D., Berlinicke, C. A., Han, H., Anders, N. M., Hemingway, A., Leo, K. T., Chou, R. T., Kwon, H., et al. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-00987-6 · Cited by 23 · see citing works
Therapeutic Inertia is a Problem for All of Us
Avramidis, I., Apsemidou, A., Lalia, A. Z., Petridis, N., Tourtouras, E., Kalopitas, G., & Pilianidis, G. (2019) · Clinical Diabetes · doi:10.2337/cd19-0090 · Cited by 24 · see citing works
Loftus, J., Chen, Y., Alvir, J. M. J., Chi, L., Dasgupta, S., Gupta, A., & Wajnrajch, M. P. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1982682 · Cited by 20 · see citing works
Miller, B. S., & Yuen, K. C. J. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s336285 · Cited by 20 · see citing works
Billings, L. K., Handelsman, Y., HEILE, M. K., Schneider, D., & Wyne, K. L. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.9-a.s30 · Cited by 21 · see citing works
Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review
Martin, V. T., Samaan, K. H., Aurora, S. K., Pearlman, E. M., Zhou, C., Li, X., & Pallay, R. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01319-9 · Cited by 18 · see citing works
Girges, C., Vijiaratnam, N., Athauda, D. S., Auld, G., Gandhi, S., & Foltynie, T. (2021) · Drugs & Aging · doi:10.1007/s40266-021-00853-7 · Cited by 18 · see citing works
Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology
Zhou, Q., Li, G., Hang, K., Li, J., Yang, D., & Wang, M. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061324-011832 · Cited by 16 · see citing works
Tzanetakos, C., Bargiota, Α., Kourlaba, G., Gourzoulidis, G., & Maniadakis, N. (2017) · Clinical Drug Investigation · doi:10.1007/s40261-017-0586-0 · Cited by 16 · see citing works
Instituting a successful discharge plan for patients with type 2 diabetes: challenges and solutions
Demidowich, A. P., Batty, K., & Zilbermint, M. (2022) · Diabetes Spectrum · doi:10.2337/dsi22-0013 · Cited by 15 · see citing works
Victorino, D. B., Nejm, M. B., Guimarães‐Marques, M., Scorza, F. A., & Scorza, C. A. (2021) · Pharmaceutical Medicine · doi:10.1007/s40290-020-00374-5 · Cited by 15 · see citing works
Patel, D. K. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13224 · Cited by 14 · see citing works
Fernando, K., Bain, S. C., Holmes, P., Jones, P. N., & Patel, D. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01116-9 · Cited by 16 · see citing works
Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
Galstyan, G. R., Анатольевна, К. Е., & Александровна, Ю. Е. (2017) · Diabetes Mellitus · doi:10.14341/dm8804 · Cited by 14 · see citing works
Schürmann, D., Rudd, D. J., Schaeffer, A., Lepeleire, I. D., Friedman, E. J., Robberechts, M., Zhang, S., Liu, Y., Kandala, B., Keicher, C., et al. (2021) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002834 · Cited by 11 · see citing works
Rationale for treatment options for mealtime glucose control in patients with type 2 diabetes
Aronoff, S. L. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1285191 · Cited by 11 · see citing works
Exenatide Once Weekly for Management of Type 2 Diabetes: A Review
Inaishi, J., & Saisho, Y. (2022) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s288846 · Cited by 11 · see citing works
Semaglutide once-weekly: improved efficacy with a new safety warning
Coon, S. A., Crannage, E. F., Kerwin, L. C., & Guyton, J. E. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1534201 · Cited by 10 · see citing works
Alkhatib, N. S., Almutairi, A. R., Alkhezi, O. S., Alfayez, O. M., Yami, M. S. A., & Almohammed, O. A. (2022) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2022.01.018 · Cited by 10 · see citing works
Pieber, T. R., Leohr, J. K., Bue‐Valleskey, J. M., Juneja, R., Chien, J. Y., Syring, K. E., & Buse, J. B. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.06.007 · Cited by 10 · see citing works
Ingrasciotta, Y., Vitturi, G., & Trifirò, G. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13072113 · Cited by 9 · see citing works
Velazquez, E. P., Miller, B. S., & Yuen, K. C. J. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2290495 · Cited by 9 · see citing works
Economic Evaluation of Once-Weekly Insulin Icodec from Italian NHS Perspective
Torre, E., Matteo, S. D., Bruno, G. M., Martinotti, C., Bottaro, L. C., & Colombo, G. L. (2024) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s475461 · Cited by 8 · see citing works
Weekly Insulin Becoming a Reality
Skyler, J. S. (2021) · Diabetes Care · doi:10.2337/dci21-0011 · Cited by 8 · see citing works
Pan, Y., Shi, S., Lao, X., Zhang, J., Tan, S., Wu, Z., & Huang, J. (2016) · Peptides · doi:10.1016/j.peptides.2016.11.009 · Cited by 8 · see citing works
Zhou, A. Y., & Trujillo, J. M. (2018) · Diabetes Spectrum · doi:10.2337/ds17-0048 · Cited by 8 · see citing works
Helwig, U., Kostev, K., & Schmidt, C. (2020) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001323 · Cited by 8 · see citing works
Self-citationJi, L., Ahmann, A., Åhrén, B., Capehorn, M., Hu, P., Lingvay, I., Liu, W., Rodbard, H. W., Shen, Z., & SORLI, C. H. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15309 · Cited by 7 · see citing works
Gao, L., Bian, F., Pan, T., Jiang, H., Feng, B., Jiang, C., Sun, J. M., Xiao, J., Yan, P., & Ji, L. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16014 · Cited by 7 · see citing works
Sims, T. J., Boye, K. S., Robinson, S. J., & Kennedy‐Martin, T. (2022) · Patient Preference and Adherence · doi:10.2147/ppa.s367046 · Cited by 7 · see citing works
Current treatment for diabetes: a holistic approach
Mourelatou, N. G., Kounatidis, D. C., Vallianou, N. G., Daniele, G., Dardano, A., & Rebelos, E. (2025) · HORMONES · doi:10.1007/s42000-025-00734-3 · Cited by 7 · see citing works
Icodec: A Novel Once-Weekly Basal Insulin for Diabetes Management
Goldman, J. D., Triplitt, C. L., & Isaacs, D. M. (2024) · Annals of Pharmacotherapy · doi:10.1177/10600280241287790 · Cited by 5 · see citing works
Donnelly, L. A., Singh, K., McCrimmon, R. J., & Pearson, E. R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70269 · Cited by 5 · see citing works
Baba, Y., Watanabe, S., Hayashi, S., Sakai, T., Naka, M., Kami, S., Hirayama, K., Koizumi, K., Takahashi, A., Meguro, M., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15823 · Cited by 5 · see citing works
Akazawa, M., Shima, D., Sato, T., Shoji, E., LoPresti, M., & Nishi, R. (2022) · Patient Preference and Adherence · doi:10.2147/ppa.s380871 · Cited by 5 · see citing works
Cardiovascular outcome trials in type 2 diabetes: A nurse practitioner perspective
Kruger, D. F. (2018) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000126 · Cited by 4 · see citing works
Tang, Y., Pan, X., Peng, G., & Tong, N. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.844724 · Cited by 4 · see citing works
Heisey, H. D., Gregg, L. P., Verrico, C. D., Villareal, D. T., & Fletcher, T. L. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70913 · Cited by 3 · see citing works
Wettergreen, S. A., Stewart, M. P., Kennedy, K., & Trujillo, J. M. (2022) · Diabetes Spectrum · doi:10.2337/ds21-0108 · Cited by 3 · see citing works
What Is the Role of Basal Weekly Insulin in Clinical Practice? The State of the Art
Argano, C., Priola, L., Manno, F., & Corrao, S. (2024) · Biomedicines · doi:10.3390/biomedicines12040900 · Cited by 3 · see citing works
Griffin, T. P., & Dinneen, S. F. (2021) · Annals of Internal Medicine · doi:10.7326/acpj202103160-034 · Cited by 3 · see citing works
Kruger, D. F., MAGWIRE, M. L., & Urquhart, S. (2024) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000001065 · Cited by 2 · see citing works
Incretins for management of obesity and obstructive sleep apnea
Hu, X., Yee, B. J., Phillips, C. L., Chapman, J. L., & Grunstein, R. R. (2025) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2025.2513516 · Cited by 2 · see citing works
Hinnen, D. A. (2018) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000115 · Cited by 2 · see citing works
Martens, T., Battelino, T., Heller, S. R., Bhargava, A., Ji, L., Murthy, S., Threlkeld, R. J., Li, X., Murro, A. L., Syring, K. E., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70419 · Cited by 1 · see citing works
Masseria, C., & Roeder, C. (2024) · Journal of Medical Economics · doi:10.1080/13696998.2024.2374644 · Cited by 1 · see citing works
Once-weekly glucagon-like peptide-1 receptor agonists: An overview
MAGWIRE, M. L. (2018) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000119 · Cited by 1 · see citing works
Saudi Consensus for GLP-1 RAs Switching Guidance: Consensus Report
Alsifri, S. N., Elbadawi, H., Alsabaan, F., Almahfouz, A., Alyahya, K. A., Shesha, E., Esba, L. C. A., Alnais, M., Aldahash, R., Alharbi, T., et al. (2022) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2022.131002 · Cited by 1 · see citing works
Wang, Y., Stofer, R., Wang, H., Cai, Y. C., Brent, G. A., Moin, T., & Shi, L. (2025) · Research Square · doi:10.21203/rs.3.rs-6586064/v1 · Cited by 1 · see citing works
Insulin Icodec: A Silver Lining to the Diabetic Cloud
Thomas, M., Matreja, P. S., Prakash, J. S., & Singh, N. K. (2024) · International Journal of Human and Health Sciences (IJHHS) · doi:10.31344/ijhhs.v8i1.615
Once weekly insulin in type 2 diabetes
Farmer, A. A., Patel, K. A., & Dambha‐Miller, H. (2025) · BMJ · doi:10.1136/bmj.r1931
Glucagon-Like Peptide-1 Receptor Agonists
Whitley, H. P. (2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch13
Injectables for the Treatment of Hypertension
Kukuev, A., Ravid, D., & Rader, F. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.03.066
Polonsky, W. H., Low, E., Dias-Barbosa, C., Clark, A., Bailey, K., Ilag, L., GONCALVES, L. F., Threlkeld, R. J., Child, C. J., Davidson, M. B., et al. (2026) · Patient · doi:10.1007/s40271-026-00829-y
- Authors
- Kostev, K., Ouwens, M., Grandy, S., Johnsson, K. M., & Qiao, Q.
- Affiliations
- IQVIA (United States) (US)
- AstraZeneca (Sweden) (SE)
- AstraZeneca (United States) (US)
- Corresponding author
- Kostev, Karel
- Venue
- Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2016-06
- Volume
- Volume 9
- Pages
- 201-205
- ISSN
- 1178-7007 (ISSN-L)
- PMC
- PMC4934555
- OpenAlex
- W2462710388
- Cited by
- 92
- References
- 13
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 15 · 2023: 5 · 2022: 17 · 2021: 13 · 2020: 9 · 2019: 7 · 2018: 7 · 2017: 6 · 2016: 1
- FWCI
- 8.54
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Diabetes Metabolic Syndrome and Obesity (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- medication adherence, GLP-1 receptor agonists, exenatide once weekly, type 2 diabetes, proportion of days covered, primary care, prescription data
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
